The dualistic role of vitamin D in vascular calcifications

Kidney International

Volumn 79, Issue 7, 2011, Pages 708-714

  Razzaque, M Shawkat ^a,b  

^a HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^b The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

calcium; CKD; klotho; phosphate

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCITRIOL; DOXERCALCIFEROL; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN; MEMBRANE PROTEIN; PARICALCITOL; PHOSPHATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN ANK; PROTEIN KINASE B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ADIPOGENESIS; APOPTOSIS; ARTICLE; BIOMINERALIZATION; BLOOD VESSEL CALCIFICATION; BONE MINERALIZATION; CELL DIFFERENTIATION; CHRONIC KIDNEY DISEASE; DISEASE COURSE; GENE MUTATION; GENETIC TRANSFORMATION; HORMONE SYNTHESIS; HUMAN; HYDROXYLATION; HYPERCALCEMIA; HYPERPHOSPHATEMIA; LOSS OF FUNCTION MUTATION; MOLECULAR DYNAMICS; MORBIDITY; MORTALITY; NONHUMAN; OSTEOLYSIS; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PULSE WAVE; SIGNAL TRANSDUCTION;

EID: 79952700577     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.432     Document Type: Article

References (79)

1. McCann JC, Ames BN. Is there convincing biological or behavioral evidence linking vitamin D deficiency to brain dysfunction? FASEB J 2008; 22: 982-1001. (Pubitemid 351519955)
2. Valdivielso JM, Cannata-Andia J, Coll B et al. A new role for vitamin D receptor activation in chronic kidney disease. Am J Physiol Renal Physiol 2009; 297: F1502-F1509.
3. De Broe ME. Phosphate: despite advances in research, the benefits to patients remain limited. Kidney Int 2009; 75: 880-881.
4. Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol 2009; 296: F470-F476.
5. Deb DK, Chen Y, Zhang Z et al. 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-\{kappa\}B pathway. Am J Physiol Renal Physiol 2009; 296: F1212-F1218.
6. Verstuyf A, Carmeliet G, Bouillon R et al. Vitamin D: a pleiotropic hormone. Kidney Int 2010; 78: 140-145.
7. Razzaque MS. The FGF23 Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009; 5: 611-619.
8. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005; 289: F8-28.
9. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281.
10. Merke J, Hofmann W, Goldschmidt D et al. Demonstration of 1,25(OH)2 vitamin D3 receptors and actions in vascular smooth muscle cells in vitro. Calcif Tissue Int 1987; 41: 112-114.
11. Rajasree S, Umashankar PR, Lal AV et al. 1,25-dihydroxyvitamin D3 receptor is upregulated in aortic smooth muscle cells during hypervitaminosis D. Life Sci 2002; 70: 1777-1788. (Pubitemid 34178363)
12. Somjen D, Weisman Y, Kohen F et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111: 1666-1671. (Pubitemid 40525167)
13. Zehnder D, Bland R, Chana RS et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: a novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 2002; 13: 621-629. (Pubitemid 34183926)
14. Carthy EP, Yamashita W, Hsu A et al. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 1989; 13: 954-959. (Pubitemid 19157996)
15. Tukaj C, Kubasik-Juraniec J, Kraszpulski M. Morphological changes of aortal smooth muscle cells exposed to calcitriol in culture. Med Sci Monit 2000; 6: 668-674.
16. Rebsamen MC, Sun J, Norman AW et al. 1alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circ Res 2002; 91: 17-24. (Pubitemid 34778937)
17. Chau TS, Lai WP, Cheung PY et al. Age-related alteration of vitamin D metabolism in response to low-phosphate diet in rats. Br J Nutr 2005; 93: 299-307.
18. Lanske B, Razzaque MS. Vitamin D and aging: old concepts and new insights. J Nutr Biochem 2007; 18: 771-777. (Pubitemid 350138431)
19. Shimada T, Yamazaki Y, Takahashi M et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 2005; 289: F1088-F1095. (Pubitemid 41447065)
20. Ohnishi M, Nakatani T, Lanske B et al. Reversal of mineral ion homeostasis and soft-tissue calcification of klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int 2009; 75: 1166-1172.
21. Ichikawa S, Imel EA, Kreiter ML et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007; 117: 2684-2691. (Pubitemid 47494368)
22. Chefetz I, Heller R, Galli-Tsinopoulou A et al. A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum Genet 2005; 118: 261-266. (Pubitemid 41672088)
23. Benet-Pages A, Orlik P, Strom TM et al. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 2005; 14: 385-390. (Pubitemid 40220655)
24. Guerin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021. (Pubitemid 30410374)
25. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol 2008; 19: 213-216. (Pubitemid 351240642)
26. El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis 2007; 14: 54-66. (Pubitemid 46014536)
27. Towler DA, Shao JS, Cheng SL et al. Osteogenic regulation of vascular calcification. Ann N Y Acad Sci 2006; 1068: 327-333. (Pubitemid 43824164)
28. Razzaque MS, St-Arnaud R, Taguchi T et al. FGF-23, vitamin D and calcification: the unholy triad. Nephrol Dial Transplant 2005; 20: 2032-2035. (Pubitemid 41510074)
29. Mori K, Shioi A, Jono S et al. Expression of matrix Gla protein (MGP) in an in vitro model of vascular calcification. FEBS Lett 1998; 433: 19-22. (Pubitemid 28386723)
30. Jono S, Ikari Y, Vermeer C et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 2004; 91: 790-794. (Pubitemid 38477460)
31. Gheduzzi D, Boraldi F, Annovi G et al. Matrix Gla protein is involved in elastic fiber calcification in the dermis of pseudoxanthoma elasticum patients. Lab Invest 2007; 87: 998-1008. (Pubitemid 47429193)
32. Hur DJ, Raymond GV, Kahler SG et al. A novel MGP mutation in a consanguineous family: review of the clinical and molecular characteristics of Keutel syndrome. Am J Med Genet A 2005; 135: 36-40. (Pubitemid 40627661)
33. El-Maadawy S, Kaartinen MT, Schinke T et al. Cartilage formation and calcification in arteries of mice lacking matrix Gla protein. Connect Tissue Res 2003; 44(Suppl 1): 272-278. (Pubitemid 36395456)
34. Ho AM, Johnson MD, Kingsley DM. Role of the mouse ank gene in control of tissue calcification and arthritis. Science 2000; 289: 265-270. (Pubitemid 30469899)
35. Narisawa S, Harmey D, Yadav MC et al. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 2007; 22: 1700-1710. (Pubitemid 351235136)
36. Babij P, Roudier M, Graves T et al. New variants in the Enpp1 and Ptpn6 genes cause low BMD, crystal-related arthropathy, and vascular calcification. J Bone Miner Res 2009; 24: 1552-1564.
37. Raggi P, Bellasi A. Clinical assessment of vascular calcification. Adv Chronic Kidney Dis 2007; 14: 37-43. (Pubitemid 46014535)
38. Mizobuchi M, Towler D, Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 2009; 20: 1453-1464.
39. Al-Aly Z, Shao JS, Lai CF et al. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr-/- mice. Arterioscler Thromb Vasc Biol 2007; 27: 2589-2596. (Pubitemid 350158910)
40. Cheng SL, Shao JS, Charlton-Kachigian N et al. MSX2 promotes osteogenesis and suppresses adipogenic differentiation of multipotent mesenchymal progenitors. J Biol Chem 2003; 278: 45969-45977. (Pubitemid 37432744)
41. Tukaj C. Enhanced proliferation of aortal smooth muscle cells treated by 1,25(OH)2D3 in vitro coincides with impaired formation of elastic fibres. Int J Exp Pathol 2008; 89: 117-124. (Pubitemid 351365191)
42. Goldsmith DJ, Covic A, Sambrook PA et al. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997; 77: 37-43. (Pubitemid 27395339)
43. Briese S, Wiesner S, Will JC et al. Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy. Nephrol Dial Transplant 2006; 21: 1906-1914. (Pubitemid 43985719)
44. Bas A, Lopez I, Perez J et al. Reversibility of calcitriol-induced medial artery calcification in rats with intact renal function. J Bone Miner Res 2006; 21: 484-490.
45. Henley C, Colloton M, Cattley RC et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol Dial Transplant 2005; 20: 1370-1377. (Pubitemid 41430610)
46. Niederhoffer N, Bobryshev YV, Lartaud-Idjouadiene I et al. Aortic calcification produced by vitamin D3 plus nicotine. J Vasc Res 1997; 34: 386-398. (Pubitemid 27414508)
47. Haffner D, Hocher B, Muller D et al. Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J Hypertens 2005; 23: 1067-1075. (Pubitemid 40637927)
48. Shroff R, Egerton M, Bridel M et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 2008; 19: 1239-1246.
49. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315. (Pubitemid 43673410)
50. Razzaque MS. Therapeutic potential of klotho-FGF23 fusion polypeptides: WO2009095372. Expert Opin Ther Pat 2010; 20: 981-985.
51. Razzaque MS, Sitara D, Taguchi T et al. Premature aging-like phenotype in fibroblast growth factor 23 null mice is a vitamin D-mediated process. FASEB J 2006; 20: 720-722. (Pubitemid 46671193)
52. Razzaque MS, Lanske B. Hypervitaminosis D and premature aging: lessons learned from Fgf23 and Klotho mutant mice. Trends Mol Med 2006; 12: 298-305. (Pubitemid 44110001)
53. Nakatani T, Ohnishi M, Razzaque MS. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model. FASEB J 2009; 23: 3702-3711.
54. Ohnishi M, Nakatani T, Lanske B et al. In vivo genetic evidence for suppressing vascular and soft-tissue calcification through the reduction of serum phosphate levels, even in the presence of high serum calcium and 1,25-dihydroxyvitamin d levels. Circ Cardiovasc Genet 2009; 2: 583-590.
55. Nakatani T, Sarraj B, Ohnishi M et al. In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J 2009; 23: 433-441.
56. Memon F, El-Abbadi M, Nakatani T et al. Does Fgf23-klotho activity influence vascular and soft tissue calcification through regulating mineral ion metabolism? Kidney Int 2008; 74: 566-570.
57. Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-715. (Pubitemid 47373790)
58. Wu-Wong JR, Noonan W, Ma J et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther 2006; 318: 90-98.
59. Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N et al. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 2006; 17: S267-S273. (Pubitemid 44865260)
60. London GM, Guerin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620. (Pubitemid 46193327)
61. Sugden JA, Davies JI, Witham MD et al. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 2008; 25: 320-325. (Pubitemid 351322698)
62. Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511.
63. Shoji T, Shinohara K, Kimoto E et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 2004; 19: 179-184. (Pubitemid 38072630)
64. Shoben AB, Rudser KD, de Boer IH et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-1619.
65. Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1529-1539.
66. Mizobuchi M, Ogata H, Koiwa F et al. Vitamin D and vascular calcification in chronic kidney disease. Bone 2009; 45(Suppl 1): S26-S29.
67. Nabeshima Y. Toward a better understanding of Klotho. Sci Aging Knowledge Environ 2006; 2006: pe11.
68. Okazaki H, Shioi A, Hirowatari K et al. Phosphatidylinositol 3-kinase/Akt pathway regulates inflammatory mediators-induced calcification of human vascular smooth muscle cells. Osaka City Med J 2009; 55: 71-80.
69. Dervisoglu E, Kir HM, Kalender B et al. Serum fetuin-a concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. Cytokine 2008; 44: 323-327.
70. Heiss A, DuChesne A, Denecke B et al. Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem 2003; 278: 13333-13341. (Pubitemid 36800105)
71. Schafer C, Heiss A, Schwarz A et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357-366. (Pubitemid 38063764)
72. Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm 2007; 13: 397-411. (Pubitemid 47162414)
73. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
74. Mathew S, Tustison KS, Sugatani T et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol 2008; 19: 1092-1105.
75. Phan O, Ivanovski O, Nikolov IG et al. Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failure. Nephrol Dial Transplant 2008; 23: 82-90 (Pubitemid 351767422)
76. Voormolen N, Noordzij M, Grootendorst DC et al. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007; 22: 2909-2916. (Pubitemid 350093423)
77. Ohnishi M, Razzaque MS. Dietary and genetic evidence for phosphate toxicity accelerating mammalian aging. FASEB J 2010; 24: 3562-3571.
78. Razzaque MS. Phosphate toxicity: new insights into an old problem. Clin Sci doi:10.1042/CS20100377.
79. Tentori F, Albert JM, Young EW et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 2009; 24: 963-972.